Oncology clinical trials in Pennsylvania

Ziftomenib plus standard chemo for certain AML patients

This trial tests a new drug, ziftomenib, added to standard chemotherapy for adults with untreated acute myeloid leukemia (AML) who have specific gene changes (NPM1 mutation or KMT2A rearrangement). It aims to see if the combination works better than standard treatment alone.

Ziftomenib for relapsed or refractory acute myeloid leukemia

This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.

Indirect Calorimetry-Guided Parenteral Nutrition Prescribing in Oncology Patients

Adding new drugs to usual treatment for peripheral T-cell lymphoma

This trial tests whether adding one of two experimental drugs to the standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma, a rare blood cancer. It aims to see if the combination is safe and effective.

High-dose chemo and stem cell transplant for T-cell lymphoma patients in remission

This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.

Helping more Black and Latino patients join cancer trials

This study tests a new program to make it easier for Black and Latino people with cancer to join clinical trials. Your participation can help researchers learn how to improve access for everyone.

Comparing radiation plus targeted therapy vs standard chemo for head and neck cancer

This trial compares two treatments for advanced head and neck cancer in patients who cannot take the drug cisplatin. One group gets radiation plus a targeted drug called cetuximab, the other gets radiation plus standard chemotherapy. The goal is to see which approach works better and is safer for people who are not candidates for cisplatin.

Olaparib with or without bevacizumab for ovarian cancer

This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.

Compare two surgeries to lower ovarian cancer risk in BRCA1 carriers

This study compares two risk-reducing surgery plans for people with a BRCA1 genetic change to see which approach helps lower ovarian cancer risk. You may be asked to have the study procedure sooner or later depending on your chosen plan.

Sentinel lymph node mapping to reduce leg swelling after surgery

This study tests whether a special way of finding lymph nodes during hysterectomy can lower the risk of long-term leg swelling or related dysfunction in people with stage I endometrial cancer. It compares standard lymph node assessment with sentinel lymph node mapping and looks at how this affects day-to-day leg functioning.

Testing a standard approach for pleuropulmonary blastoma, with or without topotecan

This trial compares a standard surgery and chemotherapy plan for type I pleuropulmonary blastoma (PPB) to adding the drug topotecan for types II and III PPB. The goal is to see if the extra drug helps shrink tumors and improve outcomes for children with more advanced disease.

Walking Juntos: Smartphone program to help Hispanic cancer survivors be active

This study will test if a smartphone program and social media group can help Hispanic/Latino teens and young adults who had childhood cancer become more physically active. You would wear a Fitbit and use a phone app with culturally tailored tips and support.

Adding DT2216 to chemo for relapsed solid tumors and FLC

This trial is testing whether adding a new drug, DT2216, to standard chemotherapy can help treat solid tumors (not starting in the brain) or fibrolamellar carcinoma (FLC) that have come back or not responded to treatment. It's for children, teens, and young adults (ages 1 to 39).

Immunotherapy before surgery for sarcomatoid pleural mesothelioma

This trial tests adding immunotherapy before surgery to help patients with sarcomatoid pleural mesothelioma. The goal is to shrink or control the cancer and make surgery possible, while checking safety.

PYX-201 plus pembrolizumab for advanced solid tumors

This trial tests a new drug called PYX-201 combined with an immunotherapy (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help people live longer with manageable side effects.

Chemo options, with or without nivolumab, for HER2-negative stomach cancer

This Phase 3 trial compares two standard chemotherapy regimens for advanced stomach, esophagus, or gastroesophageal junction cancer that is HER2-negative. It also tests whether adding nivolumab (an immune therapy) improves outcomes.

Text message program to help rural cancer survivors quit smoking

This trial studies a text-message based program to help people who smoke quit. It targets adults in rural areas who are currently in cancer treatment and want support stopping smoking.

Pembrolizumab versus monitoring after triple-negative breast cancer response

This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.

Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response

This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.

Triptorelin to protect ovaries in young women with cancer

This study tests whether a medicine called triptorelin can protect the ovaries in young women and teens receiving strong chemotherapy for cancer. If you are newly diagnosed with a cancer (other than breast cancer) and are about to get certain chemotherapy drugs, this trial may help preserve your fertility.

Wilms tumor treatment study for children and young adults

This study is testing different treatments for children and young adults with a type of kidney cancer called Wilms tumor. The treatment you get depends on certain risk factors, like tumor stage and lab results. The goal is to give the right amount of treatment for each person's situation.

End-of-life care quality for children with cancer

This trial asks bereaved parents about the quality of care their child received in the last month of life. It aims to improve how hospitals support families when a child with cancer is dying.

New drug combinations for advanced solid tumors

This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.

Ablation treatment plus usual therapy for limited metastatic bowel cancer

This study tests whether adding “total ablation” (carefully destroying all visible small tumors using surgery, heat/cold treatment, and/or targeted radiation) to standard chemotherapy improves outcomes for people with limited spread of colorectal cancer. It may help by aiming to eliminate all known metastatic spots while you continue usual cancer treatment.